Canadian guidelines for rhinosinusitis: practical tools for the busy clinician

Shaun Kilty

Abstract
Acute bacterial rhinosinusitis (ABRS) and chronic rhinosinusitis (CRS) frequently present in clinical practice. Guidelines for management of these conditions have been published extensively in the past. However, a set of guidelines that addressed issues specific to the Canadian environment while offering clear guidance for first-line clinicians was needed, and resulted in the recent publication of Canadian clinical practice guidelines for ABRS and CRS. In addition to addressing issues specific to Canadian physicians, the presented guidelines are applicable internationally, and offer single algorithms for the diagnosis and management of ABRS and CRS, as well as expert opinion in areas that do not have an extensive evidence base. This commentary presents major points from the guidelines, as well as the intended impact of the guidelines on clinical practice.

See guidelines at: http://www.aacijournal.com/content/7/1/2

Introduction
The first comprehensive Canadian clinical practice guidelines for acute bacterial rhinosinusitis (ABRS) and chronic rhinosinusitis (CRS) have recently been co-published in Allergy Asthma Clin Immunol [1] and in J Otolaryngol Head Neck Surg [2]. Although rhinosinusitis guidelines have been issued by European and American medical societies over the last few years [3-6], and guidance for the Canadian environment has appeared [7,8], the current Canadian guidelines mark the first time that comprehensive guidelines covering both ABRS and CRS appear, with a focus on addressing issues specific to the Canadian healthcare environment.

The term rhinosinusitis is used to denote inflammation of the sinus and nasal passages, which often occur simultaneously due to their close location and shared respiratory epithelium. Rhinosinusitis is common and increasing in prevalence worldwide. It is associated with a significant burden on healthcare services, quality of patients’ lives, and lost patient productivity. The prevalence of acute rhinosinusitis increased from 11% (or 26 million) of American adults in 2006 [9] to nearly 13% (over 29 million) in 2009 [10]. Nearly 7 years ago, the economic burden of the cost of treatment was estimated at 6 billion dollars annually in the United States [11]. Clearly, as rhinosinusitis continues to affect more individuals, the impact on patient lives and total costs will also continue to rise.

Discussion
Because ABRS and CRS have different pathologies and thus management strategies, it is critical that clinicians understand these differences so appropriate treatment can be started. However, analysis of Canadian prescription data demonstrated nearly identical prescribing habits for patients with ABRS and for those with CRS [12], highlighting that differences in the treatment of these distinct conditions were not fully appreciated. The Canadian guidelines provide easy-to-read and practical recommendations to assist clinicians who face patients with symptoms of rhinosinusitis in everyday practice. These guidelines provide specific updates on a variety of topics, including diagnostic symptom duration and severity, choice of treatment, appropriate testing, and antimicrobial resistance issues, in addition to providing useful diagnostic tools. An overview of the diagnostic and treatment algorithms is presented in Figure 1.

ABRS diagnosis
The diagnosis of ABRS requires the duration of appropriate symptoms be greater than 7 days. Prior guidelines suggest 5 days with worsening symptoms or 10 days of persistent symptoms as the lower end of duration [3], or
ABRS

P  facial Pain/pressure/fullness
O  nasal Obstruction
D  nasal purulence/discolored postnasal Discharge
S  Smell disorder (hyposmia/anosmia)

≥2 PODS, one of which must be O or D, present for >7 days without improvement.

Mild  Moderate  Severe

-INCS.
- If no response within 72 hours, consider antibiotics.

-INCS.
- Antibiotics: 1st line Amoxicillin. TMP/SMX or macrolide for β-lactam allergy.
- 2nd line Amoxicillin/clavulanic acid combination or fluoroquinolone for risk of resistance, risk of complications, or 1st-line failure.

CRS

C  facial Congestion/fullness
P  facial Pain/pressure
O  nasal Obstruction
D  purulent nasal Drainage
S  Smell disorder (hyposmia/anosmia)

≥2 CPODS + ≥1 objective finding (endoscopy/CT), present for 8-12 weeks. Determine CRSSNP vs CRSwNP.

Mild  Moderate  Severe*

-INCS.
- Antibiotics (2nd line).
- Consider: short course oral steroids, saline irrigation, specialist assessment.
- If no response in 4 weeks, refer for surgical evaluation.

-INCS.
- Short course oral steroids.
- Antibiotic if symptoms of infection.
- Consider: allergy testing, leukotriene receptor antagonist, specialty referral.
- If no response in 2-4 months, refer to surgeon.

*Severe symptoms of CRS require immediate referral.

Figure 1 Overview of algorithms for ABRS and CRS

Symptoms that persist more than 10 days after viral symptoms present, or worsen within 10 days of initial improvement [5]. Although symptoms of viral infections may linger, they reach peak severity by 3 days [13,14]. Thus, the current guidelines recommend that ABRS be considered for symptoms lasting longer than 7 days without improvement, or for symptoms that worsen after 5 to 7 days, or for symptoms that persist after 10 days.

A unique offering of these guidelines is the mnemonic, PODS stands for facial Pain/pressure/fullness, nasal Obstruction, nasal purulence/postnasal Discharge, and Smell alterations (hyposmia/anosmia). For a diagnosis, at least 2 of these major symptoms must be present, one of which must be O (obstruction) or D (discharge). To my knowledge, this is the first set of guidelines offering such a mnemonic for the major diagnostic criteria of ABRS, which should help clinicians quickly assess the information that is needed for a diagnosis. The guidelines also provide a discussion of prediction rules that describe symptoms whose cumulative presence increases the likelihood of bacterial infection. In the absence of diagnostic tests, ABRS diagnosis relies on clinical symptoms coupled with duration despite challenges in the accuracy and specificity of signs and symptoms.

ABRS treatment

Symptom severity plays a role in determining appropriate therapeutic intervention. Previous guidelines have defined symptom severity either on scores from a visual analogue score [3] or based upon temperature and pain severity [5]. The Canadian guidelines base severity by the degree to which symptoms impair the patient. Thus, low severity is defined as easily tolerated symptoms, moderate severity reflects steady symptoms that are tolerable, and severe severity indicates that symptoms are difficult to tolerate or interfere with sleep or daily activities. This approach does not depend on the presence of fever, which is not included as a major symptom of ABRS. Symptom severity is then used to determine therapeutic intervention. For symptoms that are mild to moderate in intensity, the guidelines recommend the
use of intranasal corticosteroids (INCS)—but not antibiotics—as a first step in treatment. In mild to moderate severity illness, antibiotics are reserved for patients who fail to respond to INCS after 3 days and whose symptoms continue for more than 7 days. For patients presenting with severe illness, INCS and antibiotics are recommended in combination as a first step in treatment. This approach thus reserves antibiotics for clear cases of ABRS that are not resolving spontaneously.

In general, amoxicillin remains the first-line choice for ABRS, with trimethoprim/sulfamethoxazole (TMP/SMX) or macrolides recommended for individuals with β-lactam allergy. However, antibiotic choice depends upon other considerations as well, including local antimicrobial resistance patterns, patient risk of resistance, and risk of complications of failure due to underlying disease. For patients with risk of resistance or complications of first-line failure, a second-line agent (amoxicillin/clavulanic acid combinations, fluoroquinolones) is recommended.

**CRS diagnosis**

A useful mnemonic for quick recall of major symptoms of CRS is CPODS, standing for facial Pain/pressure, nasal Obstruction/blockage, nasal Drainage, and Smell dysfunction (hyposmia/anosmia). At least two of the CPODS symptoms must be present for 8 to 12 weeks, along with documented inflammation of the nasal mucosa or paranasal sinuses. The duration of symptoms for diagnosis has generally been proposed as 12 weeks [3,5]. However, Canadian guidelines align with others in recommending an 8 week minimum for CRS diagnosis [15]. The guidelines also highlight the insistence of clinical or radiologic evidence in addition to clinical symptoms in order to make a diagnosis of CRS. Hence, a diagnosis requires the presence of 2 or more CPODS, present for 8 to 12 weeks, plus objective evidence using either endoscopy or computed tomography. A recent study of EP3OS symptom criteria confirmed by endoscopy reported moderate reliability of symptom-based diagnosis for CRS, and found stability between geographic regions [16]. These findings concur with an earlier study that found that endoscopy was critical to increase the specificity, and positive and negative predictive values for symptom-based diagnosis of CRS [17]. Although symptom-based diagnosis had poor specificity by itself, diagnostic accuracy improved dramatically when combined with an objective finding (odds ratio for CRS improved from 1.1 to 4.6 [95% CI, 2.3-9.2]).

The presence or absence of nasal polyps is used to further categorize disease. The presence of bilateral polyps in the middle meatus characterizes CRS with nasal polyps (CRSwNP), while the lack of polyps constitutes CRS without nasal polyps (CRSsNP). The guidelines provide detailed description of the physical examination, including adequate tools for visual rhinoscopy assessments and description of clinical signs, which should provide clinicians with a better understanding of useful signs and symptoms.

**CRS treatment**

Because CRS is primarily an inflammatory disease with unknown contributions from bacteria, cytokines, leukocytes, and tissue remodeling, treatment is based upon use of INCS as monotherapy or as adjunct therapy with antibiotics. Before initiating one of these treatments, predisposing and contributing conditions should be identified and treated. Conditions that are thought to contribute to CRS include allergic rhinitis, asthma, ciliary dysfunction, immune dysfunction, lost ostia patency, aspirin-exacerbated respiratory disease, and cystic fibrosis.

Nasal or oral corticosteroids are used with or without antibiotics for initial treatment of CRSsNP. When prescribed, antibiotics should be a second-line agent with broad-spectrum coverage (ie, amoxicillin-clavulanic acid inhibitors, fluoroquinolones) and duration of therapy should be longer than for ABRS.

For CRSwNP, a course of topical INCS and short courses of oral steroids are used. Antibiotics are not recommended for CRSwNP unless there are symptoms suggesting infection.

**Role of antibiotics**

These guidelines discuss concerns of increasing rates of antibiotic resistance, with the emergence of penicillin, macrolide, and multi-drug resistant *S. pneumoniae*. Elevated rates of β-lactamase-producing *H. influenzae* and *M. catarrhalis* have also been reported, with consequences for antibiotic choice. Although antibiotic resistance rates increased between 1988 and 2005, some rates have stabilized in the 5-year period between 2000 and 2005, including rates for ciprofloxacin, penicillin, and TMP/SMX resistance [18,19]. However, resistance rates continue to increase for erythromycin and tetracycline, and penicillin nonsusceptibility remains elevated. Resistance and nonsusceptibility rates also showed regional differences. Similar patterns of variable and growing antibiotic resistance are of global concern, with the World Health Organization dedicating World Health Day 2011 to the topic of antimicrobial resistance. Because of the trends in resistance rates, guidelines advise judicious use of antibiotic therapy and awareness of related issues, with appropriate selection of therapy for clinical situation.

**Ancillary therapy, testing, and prevention**

Saline irrigation has emerged in these guidelines as a strong recommendation from the experts despite limited evidence. This expert endorsement is in line with the
increased recognition of the benefits of saline therapy over the last 5 to 10 years in the management of sinonasal disease. Multiple studies report the benefit of saline irrigation in patients with CRS [20-22], ARS [23], and in allergic, acute and chronic rhinosinusitis [24]. The use of saline irrigation as adjunct therapy is primarily based upon reported symptomatic improvement and its good safety profile.

The expert panel endorsed allergy testing in cases of recurrent episodes of ABRS or for CRS as a potential contributing condition to these diseases. Indeed, studies have reported that over half of patients with recurrent ARS or with CRS tested positive for allergies [25,26]. Whether allergy treatment helps minimize symptoms in these cases is not known, but knowledge and avoidance of identified allergens remains a prudent approach none the less.

Prevention of illness is a recommendation. The importance of hand washing is highlighted as fundamental to reduce viral transmission and prevent the development of ABRS and acute exacerbations of CRS. Although studies are lacking, the expert recommendation strongly encourages educating patients regarding strategies to reduce the likelihood of contracting a viral illness.

Guideline rationale and method

The Canadian clinical practice guidelines for acute and chronic rhinosinusitis were designed foremost to be a valuable tool for first-line clinicians, particularly primary care providers. As such, the guidelines are evidence based, make specific recommendations, and comprehensively address both ABRS and CRS in single algorithms for each, while also providing the practitioner with the opinion of clinical experts.

Previous Canadian guidelines were either outdated or did not provide guidance for practitioners in best practices management of patients with ABRS or CRS. The current guidelines present strategies relevant for Canadian practitioners to negotiate the unique aspects of their healthcare system, while remaining sufficiently general to benefit an international audience. Thus, in situations that might arise in the Canadian healthcare system, such as delays in obtaining a computed tomography scan or specialist referral, action points during this waiting period are presented. However, the statements and discussions throughout the document focus on aspects central to ABRS and CRS, and apply in any healthcare environment. Advances in the pathobiology of these disease entities are discussed, along with the current status of treatment options.

The guidelines were constructed using an evidence-based strategy and present an evidence strength rating, plus a second rating that reflects the endorsement level of the multidisciplinary group of experts who represent medical fields involved in treating this multifaceted condition. This latter rating is particularly useful in areas where rigorous trials are lacking in quality or number. The guidelines were further reviewed and endorsed by the Association of Medical Microbiology and Infectious Disease Canada, Canadian Society of Allergy and Clinical Immunology, Canadian Society of Otolaryngology-Head and Neck Surgery (CSO-HNS), Canadian Association of Emergency Physicians, and the Family Physicians Airways Group of Canada.

The Canadian guidelines provide clear definitions and discussion of ABRS and CRS. The diagnostic and treatment flow diagrams are complete, providing detail and ease of flow within a single algorithm for ABRS and for CRS. The guidelines were designed to improve the ‘usability’ for general practitioners and family medicine physicians. In addition, these guidelines provide current, clear information for the optimal management of CRS—a disease entity for which advances in understanding its pathobiology and effective management strategies continue to evolve. The steps involved in the diagnosis, management, and referral of ABRS and CRS, coupled with strength of recommendation ratings, should help arm general practitioners with the information necessary to improve the management of their patients with symptoms of rhinosinusitis.

Conclusion

The knowledge base of ABRS and CRS pathology and management continues to grow and evolve as the role of pathogens are discerned, antimicrobial resistance rates change, and treatment strategies are improved. The Canadian guidelines recognize this changing environment and provide a solid foundation for future developments. The guidelines are a much-needed user-friendly tool for busy physicians who want to quickly grasp the appropriate methods of diagnosis and management of ABRS and CRS. The inclusion of mnemonic devices to aid in diagnosis, succinct algorithms for each disease entity, and expert opinion to aid where studies are lacking create a new level of utility for rhinosinusitis guidelines. Physicians who desire to understand the current state of the pathologies and treatment approaches for ABRS and CRS will benefit from these guidelines, and as an extension, their patients will benefit as well.

List of abbreviations
ABRS: acute bacterial rhinosinusitis; CRS: chronic rhinosinusitis; INCS: intranasal corticosteroids; TMP/SMX: trimethoprim/sulfamethoxazole.

Acknowledgements and funding
The author thanks Lynne Isbell, PhD for editorial assistance, which was funded by CSO-HNS.
Competing interests
The author declares that they have no competing interests.

Received: 25 March 2011 Accepted: 1 February 2012
Published: 1 February 2012

References
1. Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. Allergy Asthma Clin Immunol 2007; 2.
2. Desrosiers M, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, Evans GA, Keith PK, Wright ED, Kaplan A, Bouchard J, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. J Otolaryngol Head Neck Surg 2011; 40(Suppl 2):S99-193.
3. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyposis 2007. Rhinol Suppl 2007, 1-136.
4. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D, Walker SM, Clark AT, Dixon TA, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008, 38:19-42.
5. Rosenfeld RM, Andes D, Bhattacharyya N, Cheung D, Eisenberg S, Ganai TQ, Gelzer A, Hamilos D, Haydon RC, Hudgins PA, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007; 137:51-31.
6. Scadding GK, Durham SR, Mirakian R, Jones NS, Drake-Lee AB, Ryan D, Dixon TA, Huber PA, Nasser SM. BSACI guidelines for the management of rhinosinusitis and nasal polyposis. Clin Exp Allergy 2008, 38:260-275.
7. Desrosiers M, Frenkiel S, Hamid QA, Low D, Small P, Carr S, Hawke M, Kirkpatrick D, Lavigne F, Mandell L, et al. Acute bacterial sinusitis in adults: management in the primary care setting. J Otolaryngol 2002, 31(Suppl 2):S2-14.
8. Diagnosis and management of acute bacterial sinusitis: adults. 2008 Update. [http://www.topalbertadoctors.org/cpgs.php?sid=15&cpg_cats=56].
9. Pleis J, Lucas J. Summary health statistics for U.S. adults: National Health Interview Survey, 2007. National Center for Health Statistics. Vital Health Stat 2009, 10.
10. Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. Hyattsville, MD: National Center for Health Statistics; 2010, Series 10, No. 249.
11. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 2004, 193:3-5.
12. IMS Health: Canadian Disease and Therapeutic Index (CDTI) database. 2006.
13. Gwaltney JM Jr, Hendley JO, Pariie JT. Symptom severity patterns in experimental common colds and their usefulness in timing onset of illness in natural colds. Clin Infect Dis 2003, 36:714-723.
14. Gwaltney JM Jr. Rhinovirus infection of the normal human airway. Am J Respir Crit Care Med 1995, 152:536-39.
15. Slavin RG, Spector SL, Bernstein IL, Kaliner MA, Kennedy DW, Virant FS, Wald ER, Khan DA, Blessing-Moore J, Lang DM, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2003, 111:S13-47.
16. Tomassen P, Newsom RB, Hoffmans R, Lotvall J, Cardell LO, Gromnijdootis M, Thilsing T, Matricardi P, Kramer U, Makowska JS, et al. Reliability of EPISO symptom criteria and nasal endoscopy in the assessment of chronic rhinosinusitis—a GA(2) LEN study. Allergy 2011, 66:556-561.
17. Bhattacharyya N, Lee LN. Evaluating the diagnosis of chronic rhinosinusitis based on clinical guidelines and endoscopy. Otolaryngol Head Neck Surg 2010, 143:147-151.
18. Green K, McGregor A, Church D, Weiss K, Davidson R, Hoban D, Kibsey P, Kuhn M, Toye B, Pong-Porter S, et al. Trends in antimicrobial resistance in Canadian strains of Streptococcus pneumoniae, 1988-2003. 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 9/14/2003 Chicago, 2003.
19. Green K, Pong-Porter S, Plevnesi A, McGregor A, Low EE. Canadian Bacterial Surveillance Network: Trends in antimicrobial prescribing and pneumococcal resistance, Canada, 1993-2005. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 9/27/2006 San Francisco, 2006.
20. Pynnonen MA, Mukerji SS, Kim HM, Adams ME, Terrell JE. Nasal saline for chronic sinonasal symptoms: a randomized controlled trial. Arch Otolaryngol Head Neck Surg 2007, 133:1115-1120.
21. Harvey R, Hannan SA, Badia L, Scadding G. Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev 2007, CD006339.
22. Ottaviano G, Manoni G, Staffieri C, Giacomelli L, Marchese-Ragona R, Bertolin A, Staffieri A. Effects of sulphurous, salty, bromic, iodic thermal water nasal irrigations in nonallergic chronic rhinosinusitis: a prospective, randomized, double-blind, clinical, and cytological study. Am J Otolaryngol 2011, 32:315-329.
23. Hauptman G, Ryan MW. The effect of saline solutions on nasal patency and mucociliary clearance in rhinosinusitis patients. Otolaryngol Head Neck Surg 2007, 137:815-821.
24. Ural A, Oktemer TK, Kizil Y, Ileri F, Uslugu S. Impact of isotonic and hypertonic saline solutions on mucociliary activity in various nasal pathologies: clinical study. J Laryngol Otol 2009, 123:517-521.
25. Emanuel IA, Shah SB. Chronic rhinosinusitis: allergy and sinus computed tomography relationships. Otolaryngol Head Neck Surg 2000, 123:687-691.
26. Alho OP, Karttunen R, Karttunen TJ. Nasal mucosa in natural colds: effects of allergic rhinitis and susceptibility to recurrent sinusitis. Clin Exp Immunol 2004, 137:566-572.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6815/12/1/prepub

doi:10.1186/1472-6815-12-1
Cite this article as: Kitty: Canadian guidelines for rhinosinusitis: practical tools for the busy clinician. BMC Ear, Nose and Throat Disorders 2012 12:1.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit